Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06796998 · ClinicalTrials.gov registry record · Phase 2
Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
A Phase 2 study of Marginal Zone Lymphoma and Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, sponsored by Izidore Lossos, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT06796998 is a Phase 2 study of Marginal Zone Lymphoma and Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue that is actively recruiting participants, run by Izidore Lossos, MD. The registered enrollment target is 25 participants, below the 102-participant average among 49 other Marginal Zone Lymphoma trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06796998, a Phase 2 study of Marginal Zone Lymphoma and Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, is actively recruiting participants, sponsored by Izidore Lossos, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess if an investigational treatment of Epcoritamab will be beneficial for patients with Marginal Zone Lymphoma (MZL).
Conditions Studied
Interventions
- BIOLOGICAL Epcoritamab
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2025-10-13 |
| Est. Completion | 2031-04-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06796998
The ClinicalTrials.gov registry entry for NCT06796998 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 102-participant average among 49 other Marginal Zone Lymphoma trials with a reported enrollment target (75% lower). The listed sponsor is Izidore Lossos, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Marginal Zone Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Epcoritamab is the first listed.
NCT06796998 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06796998 about?
NCT06796998 is a clinical study titled "Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)". The purpose of this study is to assess if an investigational treatment of Epcoritamab will be beneficial for patients with Marginal Zone Lymphoma (MZL).
What is the current status of trial NCT06796998?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2025-10-13. Estimated completion is 2031-04-15.
What conditions does trial NCT06796998 study?
This clinical trial studies the following conditions: Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Splenic Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma.
What interventions are being tested in trial NCT06796998?
The interventions under investigation include: Epcoritamab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06796998?
This trial is sponsored by Izidore Lossos, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06796998 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Marginal Zone Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
RECRUITING · Phase 2
-
Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
RECRUITING · Phase 2
-
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
RECRUITING · Phase 2
-
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
RECRUITING · Phase 2
-
Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)
RECRUITING · Phase 2
-
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
RECRUITING · Phase 2
Explore more on PlainTrial
Marginal Zone Lymphoma
All registered trials for this condition
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
All registered trials for this condition
Florida
All trials with a study site in Florida
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.